The diversity of (68)Ga-based imaging agents
2013 (English)In: Recent Results in Cancer Research, ISSN 0080-0015, Vol. 194, 101-131 p.Article in journal (Refereed) Published
Development of new radiopharmaceuticals and their availability are crucial factors influencing the expansion of clinical nuclear medicine. The number of new 68Ga-based imaging agents for positron emission tomography (PET) is increasing greatly. 68Ga has been used for labeling of a broad range of molecules (small organic molecules, peptides, proteins, and oligonucleotides) as well as particles, thus demonstrating its potential to become a PET analog of the legendary generator-produced gamma-emitting 99mTc but with added value of higher sensitivity and resolution as well as quantitation and dynamic scanning. Further, the availability of technology for GMP-compliant automated tracer production can facilitate the introduction of new radiopharmaceuticals and enable standardized, harmonized multicenter studies to be conducted for regulatory approval. This chapter presents some examples of tracers for targeted, pretargeted, and nontargeted imaging with emphasis on the potential of 68Ga to facilitate clinically practical PET development and to promote the PET technique worldwide for earlier and better diagnostics, and personalized medicine with the ultimate objective of improved therapeutic outcome.
Place, publisher, year, edition, pages
2013. Vol. 194, 101-131 p.
Radiology, Nuclear Medicine and Medical Imaging
IdentifiersURN: urn:nbn:se:uu:diva-221806OAI: oai:DiVA.org:uu-221806DiVA: diva2:710154